Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Merck KGaA (ETR: MRCG) strengthened its full-year 2025 outlook after posting higher third-quarter earnings, supported by strong momentum in its Healthcare and Life Science divisions despite ongoing softness in the Electronics segment. The German science and technology company now expects net sales between €20.8 billion and €21.4 billion and EBITDA pre of €6 billion to €6.2 billion, reflecting organic growth of 3% and 5–7%, respectively.
The updated forecast also factors in portfolio changes, including the July 2025 acquisition of SpringWorks Therapeutics and the divestment of the Surface Solutions business. Merck projects earnings per share pre of €8.20 to €8.60, based on a 22% tax rate, and anticipates operating cash flow between €3.6 billion and €4 billion.
Merck said organic sales growth will be led primarily by its Life Science and Healthcare sectors, with Electronics expected to decline. Within Healthcare, the company foresees continued strength from its Cardiovascular, Metabolism & Endocrinology franchise. Meanwhile, multiple sclerosis treatment Mavenclad is set to remain a growth driver, although its contribution may soften after a recent U.S. court ruling that enables competing products.
In the third quarter, Merck’s net sales rose 1% to €5.32 billion, while EBIT increased 11.3% to €1.22 billion, lifting the margin to 23%. EBITDA pre climbed 3.1% to €1.67 billion, and profit after tax advanced 10.6% to €898 million. These gains were supported by divestment-related income, including a €113 million disposal gain from the Surface Solutions sale and proceeds from a $175 million FDA priority review voucher transaction.
Healthcare sales reached €2.2 billion, driven by strong performances from Mavenclad and oncology therapy Erbitux. Life Science revenue increased to €2.24 billion, supported by robust demand in Process Solutions. Electronics revenue declined 5.2% to €875 million following the divestment.
Merck ended the quarter with €1.52 billion in operating cash flow and net financial debt of €9.29 billion, reflecting new bond issuances and the SpringWorks acquisition. The company expects 2025 to remain volatile due to macroeconomic and currency factors, with the euro–U.S. dollar exchange rate likely staying between 1.11 and 1.15.
